There is controversy about whether chemotherapy or an HLA-identical sibling bone marrow transplant is better treatment for adults with acute lymphoblastic leukemia (ALL) in first remission. A previous study of patients treated in 1980-1987 showed similar leukemiafree survivals with these approaches. We re-examined this issue in more recently treated patients receiving different chemotherapy. Chemotherapy subjects (n = 76) participated in trial ALL-87 of the Japan Adult Leukemia Study Group (JALSG). Transplant subjects (n = 214) were reported to the International Bone Marrow Transplant Registry (IBMTR). Treatment-related mortality, relapse and leukemia-free survival were compared after adjusting for differences in subject-and disease-related variables and time-to-treatment. Outcomes differed in persons р and Ͼ30 years of age. Five-year treatment-related mortality in persons р30 years was 3% (95% confidence interval, 0-12%) with chemotherapy vs 32% (23-41%; P Ͻ 0.0001) with transplants. The difference was greater among persons Ͼ30 years, 13% (2-31%) with chemotherapy vs 57% (43-69%; P Ͻ 0.0001) with transplants. Five-year relapse probability in persons р30 years was 69% (50-84%) with chemotherapy vs 22% (14-32%; P Ͻ 0.0001) with transplants. Among persons Ͼ30 years, 5-year relapse was 70% (53-85%) with chemotherapy vs 32% (20-45%; P Ͻ 0.0001) with transplants. Leukemia-free survival at 5 years was significantly worse with chemotherapy than with transplants in persons р30 years (30% (15-48%) vs 53% (44-63%; P = 0.02) ) but not in persons Ͼ30 years (26% (13-41%) vs 30% (20-41%; P = 0.70) ). We concluded that transplants result in more treatmentrelated deaths but fewer relapses than chemotherapy. Leukemia-free survival is better with transplants than chemotherapy in persons р30 years of age but comparable in older persons.
Both chemotherapy and HLA-identical sibling bone marrow transplants are used for post-remission treatment of adults with acute lymphoblastic leukemia (ALL) in first remission. [1] [2] [3] Which treatment, if either, is better is controversial. Two comparative studies in which patients were assigned to receive or not receive a transplant based on donor availability reported higher treatment-related mortality but fewer relapses with transplants; leukemia-free survival and survival were comparable. 4, 5 One study suggested better leukemia-free survival with transplants in persons with high-risk features at diagnosis. 5 We previously studied this question by comparing treatment outcomes in two observational databases spanning 1980 to 1987. 6, 7 We found more treatment-related mortality but fewer relapses with transplants; leukemia-free survival was comparable. Although the transplant data set for that study included persons receiving diverse transplant regimens, the chemotherapy data set included persons receiving a single regimen. In this study, we sought to determine if our conclusions also applied to more recently treated patients and to those receiving different chemotherapy.
Materials and methods

Design
The objective was to compare treatment-related mortality, relapse and leukemia-free survival after chemotherapy vs transplants after adjusting for possibly confounding differences in subject-and disease-related variables and time-totreatment. Such a design requires availability of chemotherapy and transplant datasets with reasonably comparable patients, detailed patient-level information on pretreatment characteristics and longitudinal follow-up. The Japan Adult Leukemia Study Group (JALSG), which conducts clinical trials in adults with leukemia, maintains such a database and was interested in comparing their recent results of com-bination chemotherapy with transplant outcomes. The International Bone Marrow Transplant Registry (IBMTR) is a voluntary organization of over 300 transplant centers worldwide that provide comprehensive clinical data on their consecutive transplant recipients to a Statistical Center at the Medical College of Wisconsin. The IBMTR database includes over 30 000 patients, with data for about 40% of all allografts performed worldwide. Inclusion criteria for this study were designated according to eligibility criteria of JALSG protocols and common selection criteria for transplantation. They included: (1) diagnosis of ALL (excluding mature B cell ALL) between 1988 and 1990; (2) ages у15 and р55 years; (3) first remission duration у2 months; and (4) complete pretreatment data for age and white blood cells (WBC) at diagnosis. There were too few patients with mature B cell ALL to statistically adjust for the potential prognostic effect of this variable. Fifteen is the lower age limit for JALSG protocols and very few patients older than 55 years receive transplants. Similarly, very few patients receive a transplant Ͻ2 months after achieving first remission. Data on age and white blood cell count were needed to adjust for their prognostic effects.
Subjects
Chemotherapy cohort
One hundred and twenty-one patients entered study ALL-87 of the JALSG; 97 achieved remission. 8 Twenty-one were excluded from this analysis because of diagnosis before 1988 (n = 2), mature B cell ALL (n = 3), age Ͼ55 years (n = 11), first remission duration Ͻ2 months (n = 4) and WBC at diagnosis unknown (n = 1). Seventy-six patients were evaluable; 11 received an HLA-identical sibling bone marrow transplant in first remission (n = 9) or thereafter (n = 2). One additional patient received a transplant from a genetically identical twin. Recipients of HLAidentical sibling transplants were switched to the transplant cohort at the time of transplant. The recipient of the twin transplant was censored at the time of transplant.
Transplant cohort
An initial transplant cohort was selected from the IBMTR database using these criteria: (1) HLA-identical sibling donor; (2) year of diagnosis between 1988 and 1990; (3) ALL (excluding mature B cell ALL); (4) transplant in first remission; (5) age у15 and р55 years; and (6) interval from remission to transplant у2 months. Two hundred and fourteen patients meeting these criteria were identified and included in this study. One hundred and forty-three (69%) received total body irradiation and cyclophosphamide with or without other drugs for pretransplant conditioning, 32 (16%) received total body irradiation with drugs other than cyclophosphamide, and 31 (15%) received busulfan and cyclophosphamide. Graft-versus-host disease prophylaxis was with combined methotrexate and cyclosporine in 107 (52%) patients, cyclosporine with or without other drugs in 51 (25%), methotrexate with or without other drugs in one (1%) and T cell depletion of donor bone marrow in 47 (23%).
Outcomes
Outcomes studied were treatment-related mortality, relapse and leukemia-free survival. Treatment-related mortality was defined as death in continuous complete remission; patients were censored at relapse or last follow-up. Relapse was defined as a hematologic leukemia recurrence; patients were censored at death in remission or last follow-up. Leukemia-free survival was defined as survival without leukemia recurrence; patients were censored at last follow-up.
Statistics
Characteristics of the transplant and chemotherapy groups were compared using the 2 test and the Wilcoxon twosample test for categorical and continuous variables, respectively.
There are two potential sources of bias when comparing outcome of transplant and nontransplant therapy: differences in time to treatment (time to transplant) and differences in baseline characteristics of patients. To address the first source of bias, which results from the fact that patients must survive in remission sufficiently long for a transplant to be done, we first excluded patients with survival or remission times Ͻ2 months after remission, since very few transplants are done this early. Additionally, a left-truncated Cox regression model was used with time to transplant as the truncation time. 9, 10 At each time-point in this model, the risk set for the nontransplant cohort consists of all patients still under study while the risk set in the transplant cohort includes only those with a time from remission to transplant of less than the current time-point who are still under study. To adjust for differences in baseline characteristics, first a Cox proportional hazards regression analysis with a backwards stepwise approach was used in each treatment group separately to identify variables associated with treatment failure. Variables considered were age, year of diagnosis, immune phenotype, WBC at diagnosis, mediastinal mass at diagnosis, time from diagnosis to first remission, and time from first remission to bone marrow transplantation. Age was the only variable significantly correlated with treatment failure. Tests for interaction between treatment effect and age indicated a differential effect of treatment in patients р30 or Ͼ30 years; analyses were therefore stratified by age. The proportionality assumption of the Cox model was tested by adding a time-dependent covariate. The proportionality assumption did not hold for treatment effect (transplant vs chemotherapy), indicating that the relationship between treatment and outcome was different early and late after treatment. To determine regions of the treatment period where the relative risk between the two treatment groups was constant, a series of Cox models with different cut-off points for time-dependent treatment effects were fit. The final model was the one giving the largest partial likelihood. In this model, treatment was considered as a time-dependent covariate with different coefficients for 0-20 and Ͼ20 months after first complete remission. a Includes nine patients receiving an HLA-identical sibling transplant at a median (range) of 5 (2.4-12.8) months after first remission. These patients were considered in the chemotherapy cohort until transplant and in the transplant cohort thereafter. WBC = white blood cell count at diagnosis; CR1 = first complete remission; NA = not applicable.
Results
Comparison of chemotherapy and transplant cohorts
Patient-and disease-related variables for the chemotherapy and transplant cohorts are shown in Table 1 . Significant differences were detected in year of diagnosis (transplant cohort later) and age (transplant cohort younger).
Among those variables considered in Cox regression analysis, only age correlated with treatment failure in separate analyses of the transplant and chemotherapy cohorts. This was significant only in the transplant cohort (relative risk = 1.04; n = age increment in years; P = 0.0001). Tests for interaction indicated a differential effect of treatment in patients р or Ͼ30 years. Subsequent analyses, therefore, considered these groups separately.
Treatment outcome
Five-year probabilities of treatment outcomes are shown in Table 2 . For patients р30 years, the 5-year probability of treatment-related mortality was 3% (95% confidence interval, 0-12%) with chemotherapy vs 32% (23-41%; P Ͻ 0.0001) with transplants. The difference in treatmentrelated mortality was greater in patients Ͼ30 years, 13% (2-31%) with chemotherapy vs 57% (43-69%; P Ͻ 0.0001) with transplants. The 5-year relapse probability was 69% Table 2 Five-year probabilities (95% confidence interval) of treatment-related mortality, relapse, and leukemia-free survival (50-84%) with chemotherapy vs 22% (14-32%; P Ͻ 0.0001) with transplants in persons р30 years old and 70% (53-85%) with chemotherapy versus 32% (20-45%; P Ͻ 0.0001) with transplants in patients Ͼ30 years. Five-year leukemia-free survival was significantly lower with chemotherapy than with transplants in persons р30 years old, 30% (15-48%) vs 53% (44-63%; P = 0.02) (Figure 1 ). In patients older than 30 years, 5-year leukemia-free survival was similar with chemotherapy and transplants, 26% (13-41%) vs 30% (20-41%; P = 0.70) (Figure 2 ).
Discussion
These data indicate that HLA-identical sibling transplants are associated with more treatment-related deaths but fewer relapses than chemotherapy in adults with ALL in first remission. Five-year leukemia-free survival is better with transplants than with chemotherapy in persons р30 years old, but comparable in those older than 30 years. This conclusion differs from our previous study where we found no difference in leukemia-free survival regardless of age. 6, 7 This probably reflects less treatment-related mortality and fewer relapses in young patients transplanted more recently. In our previous study, treatment-related mortality was about 45% in transplant recipients Ͻ30 years vs 32% in the cur- Figure 1 Probability of LFS for adults with ALL in first remission, age р30 years. Numbers in parentheses indicate numbers of patients still at risk at 1, 2, 3, 4, 5 and 6 years since first remission. 
(1) (2) Figure 2 Probability of LFS for adults with ALL in first remission, age Ͼ30 years. Numbers in parentheses indicate numbers of patients at risk at 1, 2, 3, 4, 5 and 6 years since first remission.
rent study. Similarly, the relapse rate after transplant was about 35% in the previous study vs 22% in the current study. There was less difference between the two studies for older transplant recipients. Leukemia-free survival after chemotherapy was similar in both studies. There are several limitations to our study design. Although we adjusted for identified differences, such as age, the chemotherapy and transplant cohorts may differ for other, unmeasured variables. Also there were relatively few subjects in the chemotherapy cohort, especially when comparing specific age groups. This limits the power of the analyses to detect what may be clinically meaningful differences in subjects older than 30 years of age.
Our study compared chemotherapy vs transplants in first remission. It did not consider other treatment strategies, like reserving a transplant until relapse. We also considered only HLA-identical sibling transplants. Most data suggest worse outcomes after transplants from alternative donors. 11 Results of autotransplants are also disappointing. 12, 13 In summary, these data indicate that in adults р30 years old with ALL in first remission, HLA-identical sibling bone marrow transplants result in better leukemia-free survival than the chemotherapy scheme used in this study. Transplants and chemotherapy gave similar results in older persons.
